For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
5,000,000 - 10,000,000 [iU]
From 5,000,000 To 10,000,000 [iU] once every 2 day(s)
The recommended dose is in the range 5 to 10 million IU administered subcutaneously three times a week (every other day) for a period of 4 to 6 months.
The administered dose should be reduced by 50% in case of occurrence of haematological disorders (white blood cells <1,500/mm³, granulocytes <1,000/mm³, thrombocytes <100,000/mm³). Treatment should be discontinued in case of severe leukopaenia (<1,200/mm³), severe neutropaenia (<750/mm³) or severe thrombocytopaenia (<70,000/mm³).
For all patients, if no improvement on serum HBV-DNA is observed after 3 to 4 months of treatment (at the maximum tolerated dose), discontinue interferon alpha-2b therapy.